1111
|
PBT
|
Botulism
|
Clostridium botulinum
|
Toxoid
|
Michigan Department of Public Health (MDPH)
|
Clinical - Discontinued
|
Subcutaneous
|
19837283
|
NA
|
1129
|
Menomune
|
Meningococcal disease
|
Neisseria meningitidis
|
Polysaccharide
|
Sanofi Pasteur Inc.
|
Approved
|
Subcutaneous
|
NA
|
NA
|
1135
|
Mencevax ACWY
|
Meningococcal disease
|
Neisseria meningitidis
|
Subunit
|
GlaxoSmithKline Biologicals
|
Approved
|
Subcutaneous
|
NA
|
NA
|
1136
|
Quadri Meningo
|
Meningococcal disease
|
Neisseria meningitidis
|
Polysaccharide
|
Biomed Labs
|
Approved
|
Subcutaneous
|
NA
|
NA
|
1168
|
Q-VAX
|
Q Fever
|
Coxiella burnetii
|
Inactivated
|
Seqirus Pty Ltd
|
Approved
|
Subcutaneous
|
NA
|
NA
|
1206
|
Spirolept
|
Leptospirosis
|
Leptospira genus
|
Inactivated
|
Imaxio
|
Clinical - Phase 4
|
Subcutaneous
|
NA
|
NCT03497572
|
1229
|
NDBR 105
|
Q Fever
|
Coxiella burnetii
|
Inactivated
|
U.S. Army Medical Research and Development Command
|
Clinical - Withdrawn
|
Subcutaneous
|
NA
|
NCT02092142
|
1230
|
Chloroform-methanol residue (CMR)
|
Q Fever
|
Coxiella burnetii
|
Inactivated
|
NA
|
Clinical
|
Subcutaneous
|
8454328
|
NA
|
1244
|
BK1310
|
Diphtheria
|
Corynebacterium diphtheriae
|
Combination
|
Mitsubishi Tanabe Pharma Corporation
|
Clinical - Phase 3
|
Subcutaneous
|
NA
|
NCT03891758
|
1266
|
Squarekids
|
Diphtheria
|
Corynebacterium diphtheriae
|
Combination
|
Kitasato Daiichi Sankyo Vaccine Co., Ltd.
|
Clinical - Discontinued
|
Subcutaneous
|
NA
|
NCT02907216
|
1268
|
BK1301
|
Diphtheria
|
Corynebacterium diphtheriae
|
Combination
|
Mitsubishi Tanabe Pharma Corporation
|
Clinical - Phase 3
|
Subcutaneous
|
NA
|
NCT02118961
|
1269
|
DTBIK
|
Diphtheria
|
Corynebacterium diphtheriae
|
Toxoid
|
Mitsubishi Tanabe Pharma Corporation
|
Clinical - Phase 3
|
Subcutaneous
|
NA
|
NCT02118961
|
1273
|
Tetrabik
|
Diphtheria
|
Corynebacterium diphtheriae
|
Combination
|
Merck Sharp & Dohme Corp.
|
Clinical - Phase 4
|
Subcutaneous
|
NA
|
NCT01926015
|
1277
|
Squarekids
|
Pertussis (Whooping Cough)
|
Bordetella pertussis
|
Combination
|
Kitasato Daiichi Sankyo Vaccine Co., Ltd.
|
Clinical - Discontinued
|
Subcutaneous
|
NA
|
NCT02907216
|
1283
|
BK1301
|
Pertussis (Whooping Cough)
|
Bordetella pertussis
|
Combination
|
Mitsubishi Tanabe Pharma Corporation
|
Clinical - Phase 3
|
Subcutaneous
|
NA
|
NCT02118961
|
1284
|
DTBIK
|
Pertussis (Whooping Cough)
|
Bordetella pertussis
|
Toxoid
|
Mitsubishi Tanabe Pharma Corporation
|
Clinical - Phase 3
|
Subcutaneous
|
NA
|
NCT02118961
|
1291
|
BK1310
|
Pertussis (Whooping Cough)
|
Bordetella pertussis
|
Combination
|
Mitsubishi Tanabe Pharma Corporation
|
Clinical - Phase 3
|
Subcutaneous
|
NA
|
NCT03891758
|
1292
|
Tetrabik
|
Pertussis (Whooping Cough)
|
Bordetella pertussis
|
Combination
|
Merck Sharp & Dohme Corp.
|
Clinical - Phase 4
|
Subcutaneous
|
NA
|
NCT01926015
|
1296
|
Squarekids
|
Tetanus (Lock Jaw)
|
Clostridium tetani
|
Combination
|
Kitasato Daiichi Sankyo Vaccine Co., Ltd.
|
Clinical - Discontinued
|
Subcutaneous
|
NA
|
NCT02907216
|
1298
|
Tetrabik
|
Tetanus (Lock Jaw)
|
Clostridium tetani
|
Combination
|
Merck Sharp & Dohme Corp.
|
Clinical - Phase 4
|
Subcutaneous
|
NA
|
NCT01926015
|
1305
|
BK1301
|
Tetanus (Lock Jaw)
|
Clostridium tetani
|
Combination
|
Mitsubishi Tanabe Pharma Corporation
|
Clinical - Phase 3
|
Subcutaneous
|
NA
|
NCT02118961
|
1309
|
SP0204
|
Tetanus (Lock Jaw)
|
Clostridium tetani
|
Combination
|
Sanofi Pasteur, a Sanofi Company
|
Clinical - Phase 3
|
Subcutaneous
|
NA
|
NCT02274285
|
1310
|
DD 687 or DF 098
|
Tetanus (Lock Jaw)
|
Clostridium tetani
|
Combination
|
Sanofi Pasteur, a Sanofi Company
|
Clinical - Phase 3
|
Subcutaneous
|
NA
|
NCT02274285
|
1316
|
BK1310
|
Tetanus (Lock Jaw)
|
Clostridium tetani
|
Combination
|
Mitsubishi Tanabe Pharma Corporation
|
Clinical - Phase 3
|
Subcutaneous
|
NA
|
NCT03891758
|
1337
|
Meningo A+C
|
Meningococcal disease
|
Neisseria meningitidis
|
Polysaccharide
|
Sanofi Pasteur, a Sanofi Company
|
Clinical - Phase 4
|
Subcutaneous
|
NA
|
NCT01430611
|
1338
|
Meng Ling Kang
|
Meningococcal disease
|
Neisseria meningitidis
|
Polysaccharide
|
Sanofi Pasteur, a Sanofi Company
|
Clinical - Phase 4
|
Subcutaneous
|
NA
|
NCT01430611
|